Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-015175
Filing Date
2025-04-23
Accepted
2025-04-23 16:01:32
Documents
21
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20043084x1_def14a.htm   iXBRL DEF 14A 752679
6 sig_douglaslove.jpg GRAPHIC 11471
7 ny20043084x1_pc01.jpg GRAPHIC 563228
8 ny20043084x1_pc02.jpg GRAPHIC 491539
9 ny20043084x1_pvpchart01x2.jpg GRAPHIC 91960
10 ny20043084x1_pvpchart02x2.jpg GRAPHIC 88997
  Complete submission text file 0001140361-25-015175.txt   4833342

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA annx-20250605.xsd EX-101.SCH 3109
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE annx-20250605_def.xml EX-101.DEF 2566
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE annx-20250605_lab.xml EX-101.LAB 2248
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE annx-20250605_pre.xml EX-101.PRE 1717
23 EXTRACTED XBRL INSTANCE DOCUMENT ny20043084x1_def14a_htm.xml XML 293603
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39402 | Film No.: 25861338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)